236 related articles for article (PubMed ID: 7986107)
1. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
2. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
Andoh M; Fujiwara Y; Shimada Y
Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. [Introduction of anticancer agents to phase I clinical trials].
Shimoyama M
Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial design in metastatic breast cancer: a commentary.
Levine M
Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
[TBL] [Abstract][Full Text] [Related]
6. [Phase II clinical trials in patients with lung cancer].
Shinkai T; Saijo N
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():232-44. PubMed ID: 8007470
[TBL] [Abstract][Full Text] [Related]
7. [The present status and problems of phase III clinical trials of the new anti tumor drug-pharmaceutical company's view].
Yamada A
Gan To Kagaku Ryoho; 1995 Feb; 22(3):323-7. PubMed ID: 7880102
[TBL] [Abstract][Full Text] [Related]
8. [Development of anti-cancer drugs under new renewed GCP--from the viewpoint of drug development company developer].
Ueno T; Kobayashi T; Inoue K; Yanagi Y; Yamada Y
Gan To Kagaku Ryoho; 1998 Apr; 25(5):663-70. PubMed ID: 9571963
[TBL] [Abstract][Full Text] [Related]
9. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
10. [Guideline for phase I study on new anticancer agents].
Shimoyama M
Gan To Kagaku Ryoho; 2001 Feb; 28(2):261-70. PubMed ID: 11242659
[TBL] [Abstract][Full Text] [Related]
11. [Our policy and future tasks related to ICH in anti-cancer drug development--a discussion from the viewpoint of an enterprise].
Ekimoto H
Gan To Kagaku Ryoho; 1997 Jan; 24(2):229-37. PubMed ID: 9030236
[TBL] [Abstract][Full Text] [Related]
12. [The guideline for clinical trials proposed by Japan Society for Cancer Therapy (JSCT)].
Kurihara M
Gan To Kagaku Ryoho; 1996 Jan; 23(2):156-65. PubMed ID: 8611043
[TBL] [Abstract][Full Text] [Related]
13. Food and Drug Administration requirements for approval of new anticancer drugs.
Johnson JR; Temple R
Cancer Treat Rep; 1985 Oct; 69(10):1155-9. PubMed ID: 4042094
[TBL] [Abstract][Full Text] [Related]
14. [Results of questionnaire to 56 medical institutions about clinical trials of cancer chemotherapy].
Kurihara M; Matsukawa M; Satoh A; Shimada K; Asaumi H
Gan To Kagaku Ryoho; 1999 Jun; 26(7):916-25. PubMed ID: 10396318
[TBL] [Abstract][Full Text] [Related]
15. [Recent proposals for early stage clinical trials of cancer].
Ohashi Y
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():292-4. PubMed ID: 7986106
[TBL] [Abstract][Full Text] [Related]
16. Phase I cancer trials: limitations and implications.
Dillman RO; Koziol JA
Mol Biother; 1992 Sep; 4(3):117-21. PubMed ID: 1445664
[TBL] [Abstract][Full Text] [Related]
17. Ethics and errors of clinical trials and the role and place of different types of trial.
Mathé G; Reizenstein P
Drugs Exp Clin Res; 1986; 12(1-3):1-9. PubMed ID: 3732046
[TBL] [Abstract][Full Text] [Related]
18. [New oral anticancer drug, TS-1 (S-1)--from bench to clinic].
Shirasaka T; Tsukuda M; Inuyama Y; Taguchi T
Gan To Kagaku Ryoho; 2001 Jun; 28(6):855-64. PubMed ID: 11432358
[TBL] [Abstract][Full Text] [Related]
19. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
20. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
Kusaba H; Tamura T
Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
